Table 1 Descriptive statistics by Apolipoprotein E ε4 status.
From: The biphasic impact of apolipoprotein E ε4 allele on age-related hearing loss
Total (n = 1162) | ε4 (+) group (n = 280) | ε4 (−) group (n = 882) | P | ||
|---|---|---|---|---|---|
Sex | Male | 456 (39.2%) | 111 (39.6%) | 345 (39.1%) | 0.931 |
Female | 706 (60.8%) | 169 (60.4%) | 537 (60.9%) | ||
Age | Mean (SE) | 75.7 ± 9.3 | 75.1 ± 7.6 | 75.9 ± 8.6 | 0.134 |
APOE Genotypes | ε2/ε2 | 5 (0.6%) | |||
ε2/ε3 | 100 (8.6%) | ||||
ε3/ε3 | 777 (66.8%) | ||||
ε2/ε4 | 12 (4.3%) | ||||
ε3/ε4 | 240 (20.6%) | ||||
ε4/ε4 | 28 (2.4%) | ||||
MMSE | Mean (SE) | 22.76 ± 6.7 | 22.4 ± 6.0 | 22.9 ± 6.5 | 0.228 |
Normal (MMSE ≥ 24) | 671 (42.3%) | 144 (51.4%) | 527 (59.8%) | 0.017* | |
Abnormal (MMSE < 24) | 491 (57.7%) | 136 (48.6%) | 355 (40.2%) | ||
PTAa (dB HL) | Mean (SE) | 34.22 ± 17.7 | 33.0 ± 17.7 | 34.6 ± 17.8 | 0.190 |
Normal (PTA ≤ 25) | 433 (37.3%) | 122 (43.6%) | 311 (35.3%) | 0.015* | |
Hearing Loss (PTA > 25) | 729 (62.7%) | 158 (56.4%) | 571 (64.7%) | ||
SDS | Mean (SE) (n = 622) | 78.98 ± 23.87 | 82.0 ± 21.1 | 78.0 ± 24.2 | 0.054 |
Diabetes | Normal | 826 (71.1%) | 203 (72.5%) | 623 (70.6%) | 0.600 |
Abnormal | 336 (28.9%) | 77 (27.5%) | 259 (29.4%) | ||
Hypertension | Normal | 555 (47.8%) | 135 (48.2%) | 420 (47.6%) | 0.916 |
Abnormal | 607 (52.2%) | 145 (51.8%) | 462 (52.4%) | ||
Lipid tests | LDL Cholesterol (mmol/L) (n = 497) | 98.97 ± 38.12 | 101.3 ± 31.7 | 98.2 ± 34.6 | 0.390 |
HDL Cholesterol (mmol/L) (n = 596) | 51.7 ± 16.2 | 51.4 ± 16.2 | 51.8 ± 14.4 | 0.782 | |
Total Cholesterol (mmol/L) (n = 618) | 175.8 ± 45.02 | 178.5 ± 39.7 | 174.9 ± 40.4 | 0.337 | |
Triglyceride (mmol/L) (n = 606) | 120.8 ± 74.93 | 120.8 ± 65.3 | 120.8 ± 87.2 | 0.999 |
